Coherus Oncology, Inc. Debt Securities, Available-for-sale, Amortized Cost
Coherus Oncology, Inc. (CHRS) had Debt Securities, Available-for-sale, Amortized Cost of $103.63 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $103.63M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $166.24M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $163.15M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $191.47M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $103.63M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $166.24M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $163.15M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $191.47M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $237.34M 10-Q · filed 2025-08-07 |
| 2024-09-30 | $69.07M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $145.81M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $259.41M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $104.32M 8-K · filed 2025-11-13 |
| 2023-09-30 | $113.25M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $117.48M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $123.66M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $191.62M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |